As mRNA therapeutics expand into cancer vaccines, cell therapies and beyond, manufacturing high-quality mRNA with minimal byproducts is more critical than ever.
This poster explores how a novel RNA polymerase can help you reduce double-stranded RNA (dsRNA) byproducts during mRNA manufacturing, improving the tolerability, safety, and potency of potential mRNA therapies.
Key data presented:
- Achieve dsRNA reduction by up to 85% in in vitro transcription (IVT)
- Lower dsRNA levels in both mRNA and saRNA syntheses without impacting quality attributes
- Integrate effortlessly into existing IVT protocols with simple enzyme substitution
Offered Free by: TriLink
See All Resources from: TriLink
